PRECISION BIOSCIENCES INC 8K

Precision BioSciences reported Q2 2026 results and a comprehensive business update featuring encouraging PBGENE-HBV clinical data, progress in PBGENE-DMD and partnered programs, leadership changes, Russell 2000 inclusion, and a cash runway projected through 2028 despite a higher net loss from non-cash warrant revaluation.

On August 6, 2026, Precision BioSciences, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a broad business update, highlighting new clinical biopsy data from its Phase 1 ELIMINATE-B trial showing a 1-log reduction in hepatitis B cccDNA and sustained pgRNA loss in all evaluable patients treated with PBGENE-HBV, continued advancement and active recruitment in its Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, progress in partnered in vivo and ex vivo programs including iECURE’s ECUR-506 for OTC deficiency and Imugene’s/TG Therapeutics’ azer-cel programs, internal leadership changes including promotion of the former CFO to COO and appointment of a new CFO, its recent addition to the Russell 2000 Index, and financial metrics indicating a $112.4 million cash balance with an expected cash runway through 2028 despite a larger net loss driven primarily by non-cash warrant liability fair value adjustments.

Filing Facts

CIK

1357874

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-053836

Alert Tier

6